Russian Federation
Russian Federation
Russian Federation
Russian Federation
Russian Federation
The article assesses impact of the angiotensin converting enzyme inhibitors, angiotensin II receptor blockers and angiotensin receptor and neprilysin antagonists in the framework of combined cardial therapy on sSt2, NT-proBNP and Gal-3 levels in patients with stable ischemic heart disease and chronic heart failure of functional classes I–III, having suffered COVID-19 during 12 months of observation
ischemic heart disease, chronic heart failure, sSt2, galectin-3, COVID-19.
1. Maggioni A.P. Epidemiology of Heart Failure in Europe. Heart Failure Clinics. 2015; 11(4):625–35. doi:https://doi.org/10.1016/j.hfc.2015.07.015.
2. Mezhdunarodnyy registr «Analiz dinamiki komorbidnyh zabolevaniy u pacientov, perenesshih inficirovanie SARS-CoV-2» (AKTIV SARS-CoV-2): analiz prediktorov neblagopriyatnyh ishodov ostroy stadii novoy koronavirusnoy infekcii // Rossiyskiy kardiologicheskiy zhurnal. – 2021; 26(4):4470. doi:https://doi.org/10.15829/1560-4071-2021-4470
3. Begrambekova Yu.L., Vasyuk Yu.A., Garganeeva A.A. i dr. Klinicheskie rekomendacii OSSN– RKO–RNMOT. Serdechnaya nedostatochnost': hronicheskaya (HSN) i ostraya dekompensirovannaya (ODSN). Diagnostika, profilaktika i lechenie // Kardiologiya. – 2018; 58(6S):8–164. doi:https://doi.org/10.18087/cardio.2475
4. Belaya O.L., Ryzhkov I.M., Kovalenko E.V. i soavt. Prognosticheskaya rol' biomarkera rastvorimogo ST2 v ocenke riska razvitiya neblagopriyatnyh serdechno-sosudistyh sobytiy u bol'nyh ishemicheskoy bolezn'yu serdca s hronicheskoy serdechnoy nedostatochnost'yu i perenesennym COVID-19 // Medicinskiy vestnik MVD. – 2023; 3:37–41. doi:https://doi.org/10.52341/20738080-2023-124-3-37
5. Stabil'naya ishemicheskaya bolezn' serdca. Klinicheskie rekomendacii – 2020 // Rossiyskiy kardiologicheskiy zhurnal. – 2020; 25(11):4076. doi:https://doi.org/10.15829/1560-4071-2020-4076
6. Hronicheskaya serdechnaya nedostatochnost'. Klinicheskie rekomendacii – 2020 // Rossiyskiy kardiologicheskiy zhurnal. – 2020; 25(11):4083. doi:https://doi.org/10.15829/1560-4071-2020-4083
7. Alieva A.M., Baykova I.E., Kislyakov V.A. i dr. Galektin-3: diagnosticheskaya i prognosticheskaya cennost' opredeleniya u pacientov s hronicheskoy serdechnoy nedostatochnost'yu // Terapev- ticheskiy arhiv. – 2019; 91 (9): 145–149. doi:https://doi.org/10.26442/00403660.2019.09.000226
8. Michalski B., Trzciński P., Kupczyńska K. et al. The differences in the relationship between diastolic dysfunction, selected biomarkers and collagen turn-over in heart failure patients with preserved and reduced ejection fraction // Cardiol J., 2017; 24(1):35–42. doi:https://doi.org/10.5603/CJ.a2016.0098
9. Fateev S.S., Oranzhereeva V.N., Fedulov V.K. i soavt. Galektin-3 i strukturno-funkcional'nye parametry levogo zheludochka pri ishemicheskoy bolezni serdca v sochetanii s hronicheskoy bolezn'yu pochek // Kardiovaskulyarnaya terapiya i profilaktika. – 2024; 23(1):3729. doi:https://doi.org/10.15829/1728-8800-2024-3729
10. McMurray J.J., Packer M., Desai A.S., Gong J., Lefkowitz M.P., Rizkala A.R., Rouleau J.L., Shi V.C., Solomon S.D., Swedberg K., Zile M.R.; PARADIGM-HF Investigators and Committees. Angiotensinneprilysin inhibition versus enalapril in heart failure // N Engl J Med. – 2014; 371: 993–1004. doi: 10.1056/ NEJMoa1409077
11. Packer M., McMurray J.J., Desai A.S., Gong J. et al. PARADIGM-HF Investigators and Coordinators. Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure // Circulation. – 2015; 131: 54–61. doi: 10.1161/ CIRCULATIONAHA.114.013748
12. Velazquez E.J., Morrow D.A., DeVore A.D. et al. PIONEER-HF Investigators Angiotensin-neprilysin inhibition in acute decompensated heart failure // N Engl J Med. – 2019; 380:539–548. doi: 10.1056/ NEJMoa1812851
13. Zile M.R., Jhund P.S., Baicu C.F. et al. Prospective Comparison of ARNI With ARB on Management of Heart Failure With Preserved Ejection Fraction (PARAMOUNT) Investigators. Plasma Biomarkers Reflecting Profibrotic Processes in Heart Failure With a Preserved Ejection Fraction: Data From the Prospective Comparison of ARNI With ARB on Management of Heart Failure With Preserved Ejection Fraction Study // Circ Heart Fail. – 2016 Jan; 9(1):e002551. doi:https://doi.org/10.1161/CIRCHEARTFAILURE.115.002551
